fbpx

List – 91 Drug Patents that are Expiring between 2020 to 2022

Atrovant HFA
Ipratropium Bromide

Sales:
$135 million (2014)

PatentsExpiration Date
US6739333May 26, 2020
US6983743May 26, 2020

Dosage : Aerosol, Metered; Inhalation
Company : Boehringer Ingelheim Pharmaceuticals Inc
Ingredients : Ipratropium Bromide
Treatment : Chronic Obstructive Pulmonary Disease and Asthma
ANDA Filing Company : – 

Byduredon BCISE
Exenatide

Sales:
$283 million (H1,2019)

PatentsExpiration Date
US6414126October 04, 2020
US6479065August 10, 2020
US6515117October 04, 2020
US6667061May 25, 2020
US6872700January 14, 2020
US6936590October 04, 2020
US9198925October 04, 2020

Dosage : Suspension, Extended Release, Subcutaneous
Company : Astrazeneca Ab
Ingredients : Exenatide
Treatment : Type 2 Diabetes Mellitus
ANDA Filing company : –

Chantix
Varenicline

Sales:
$1.08 billion (2018)

PatentsExpiration Date
US6410550November 10, 2020

Dosage : Tablet; Oral
Company : Pfizer
Ingredients : Varenicline Tartrate
Treatment : Smoking Cessation
ANDA Filing Companies : Mylan, Ajanta Pharma, Par Pharma, Apotex

Dexilant
Dexlansoprazole

Sales:
$445 Million (2017)

PatentsExpiration Date
US6462058December 15, 2020
US6939971December 15, 2020
US7285668December 15, 2020
US9145389June 15, 2020

Dosage : Capsule, Delayed Release; Oral
Company : Takeda Pharmaceuticals Usa Inc
Ingredients : Dexlansoprazole
Treatment : Erosive Esophagitis
ANDA Filing Companies : Dr Reddy’s, Impax, Anchen, Twi Pharma

Inlyta
Axitinib

Sales:
$339 million (2017)

PatentsExpiration Date
US7141581June 30, 2020

Dosage : Tablet; Oral
Company : Pfizer
Ingredients : Axitinib
Treatment : Advanced Renal Cell Carcinoma
ANDA Filing Companies : Apotex, Glenmark

Safyral
Drospirenone; Ethinyl Estradiol; Levomefolate

Sales:
$22 million (2017)

PatentsExpiration Date
US6441168April 17, 2020

Dosage : Tablet; Oral
Company : Bayer Healthcare Pharmaceuticals Inc
Ingredients : Drospirenone; Ethinyl Estradiol; Levomefolate Calcium
Treatment : Oral Contraceptive
ANDA Filing Companies : Lupin, Watson

Saphris
Asenapine

Sales:
$139.7 million (2018)

PatentsExpiration Date
US5763476December 09, 2020

Dosage : Tablet; Sublingual
Company : Allergan Llc
Ingredients : Asenapine Maleate
Treatment : Antipsychotic
ANDA Filing Companies : Alembic, Amneal, Breckenridge, Hikma, SigmaPharma

Silenor
Doxepin

Sales:
$22.3 million (2017)

PatentsExpiration Date
US6211229February 17, 2020

Dosage : Tablet; Sublingual
Company : Currax Pharmaceuticals Llc
Ingredients : Doxepin Hydrochloride
Treatment : Sleep Problem (Insomnia)
ANDA Filing Companies : Par Pharma, Actavis, Mylan, Zydus Cadila

Sprycel
Dasatinib

Sales:
$536 million (2018)

PatentsExpiration Date
US6596746December 28, 2020
US7125875October 13, 2020
US7153856October 28, 2020

Dosage : Tablet; Oral
Company : Bristol Myers Squibb Co
Ingredients : Dasatinib
Treatment : Cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL
ANDA Filing Companies : Apotex, Dr Reddy’s

Vigamox
Moxifloxacin

Sales:
$267.9 million (2017)

PatentsExpiration Date
US6716830March 29, 2020
US7671070March 29, 2020

Dosage : Solution/Drops; Ophthalmic
Company : Novartis Pharmaceuticals Corp
Ingredients : Moxifloxacin Hydrochloride
Treatment : Bacterial Conjunctivitis
ANDA Filing Companies : Teva, Watson, Lupin, Apotex, Aurobindo, Akorn, Alembic

Xarelto
Rivaroxaban

Sales:
$6.58 billion (2018)

PatentsExpiration Date
US7585860December 11, 2020
US7592339June 24, 2022

Dosage : Tablet; Oral
Company : Janssen Pharmaceuticals Inc
Ingredients : Rivaroxaban
Treatment : Stroke and systemic embolism with nonvalvular atrial fibrillation
ANDA Filing Companies : Aurobindo, Breckenridge, Microlabs, Mylan, SigmaPharma, Torrent, Prinston Pharma, Sun (Taro), Teva, Alembic, Invagen, Lupin, Macleods, Accord (Intas), Hec Pharma

Bystolic
Nebivolol

Sales:
$585.8 million (2018)

PatentsExpiration Date
US6545040December 17, 2021

Dosage : Tablet; Oral
Company : Allergan Llc
Ingredients : Nebivolol Hydrochloride
Treatment : Hypertension
ANDA Filing Companies : Amerigen Pharma, Glenmark, Hetero, Torrent, Watson, Alkem, Aurobindo

Crixivan
Indinavir

Sales:

PatentsExpiration Date
US6689761February 10, 2021

Dosage : Capsule; Oral
Company : Merck Sharp And Dohme Corp
Ingredients :  Indinavir Sulfate
Treatment : HIV
ANDA Filing company :

Emtriva
Emtricitabine

Sales:
$15 million (2018)

PatentsExpiration Date
US6642245May 04, 2021
US6703396September 09, 2021

Dosage : Capsule; Oral
Company : Gilead Sciences Inc
Ingredients : Emtricitabine
Treatment : Combination with other antiretroviral agents, for the treatment of HIV-1 infection
ANDA Filing Companies : Cipla, Aurobindo

Hysingla ER
Hydrocodone er

Sales:
$447 million (2017)

PatentsExpiration Date
US6733783October 30, 2021
US8361499October 30, 2021
US8551520October 30, 2021
US8647667October 30, 2021

Dosage : Tablet, Extended Release; Oral
Company : Purdue Pharma Lp
Ingredients : Hydrocodone Bitartrate
Treatment : Severe Pain, Opioid (narcotic) Analgesics
ANDA Filing Companies : Alvogen,  Mylan

Perforomist
Formoterol

Sales:

PatentsExpiration Date
US6667344June 22, 2021
US6814953June 22, 2021
US7348362June 22, 2021
US7462645June 22, 2021
US8623922June 22, 2021
US9730890June 22, 2021

Dosage : Solution; Inhalation
Company : Mylan Specialty Lp
Ingredients : Formoterol Fumarate
Treatment : Chronic Obstructive Pulmonary Disease including Chronic Bronchitis and Emphysema
ANDA Filing Company : Teva

Sutent
Sunitinib

Sales:
$264 million (2018)

PatentsExpiration Date
US6573293August 15, 2021
US7125905August 15, 2021
US7211600June 22, 2021

Dosage : Capsule; Oral
Company : Pfizer
Ingredients : Sunitinib Malate
Treatment : Cancer (kidney, pancreas, and intestinal)
ANDA Filing Company : Mylan

Zomig ns
Zolmitriptan

Sales:
$43.1 million (2018)

PatentsExpiration Date
US6750237May 28, 2021
US7220767May 28, 2021

Dosage : Spray; Nasal
Company : Astrazeneca Pharmaceuticals Lp
Ingredients : Zolmitriptan
Treatment : Migraine
ANDA Filing Companies : Lannett, Par Pharma

Januvia
Sitagliptin

Sales:
$3.68 billion (2018)

PatentsExpiration Date
US6699871July 26, 2022
US7125873July 26, 2022

Dosage : Tablet; Oral
Company : Merck Sharp And Dohme Corp
Ingredients : Sitagliptin Phosphate
Treatment : Type 2 Diabetes Mellitus
ANDA Filing Companies : Apotex, Mylan, Sandoz, Sun Pharma, Teva, Watson, Zydus Cadila

Pristiq
Desvenlafaxine

Sales:
$206 million (2018)

PatentsExpiration Date
US6673838March 01, 2022
US8269040July 5, 2027

Dosage : Tablet, Extended Release; Oral
Company : Pfizer
Ingredients : Desvenlafaxine Succinate
Treatment : Major Depressive Disorder
ANDA Filing Companies : Anchen, Apotex, Dr Reddy’s, Lupin,  Mylan,  Roxane, Sandoz,  Teva, Watson, Intelli Pharma, Wockhardt, Zydus Cadila, Alembic (Breckenridge)

Vimovo
Esomeprazole/Naproxen

Sales:
$67.6 million (2018)

PatentsExpiration Date
US8557285May 31, 2022
US8852636May 31, 2022
US8858996May 31, 2022
US9161920May 31, 2022
US9198888May 31, 2022
US9345695May 31, 2022
US9707181May 31, 2022

Dosage : Tablet, Delayed Release; Oral
Company : Horizon Medicines Llc
Ingredients : Esomeprazole Magnesium; Naproxen
Treatment : Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
ANDA Filing Companies :

Vimpat
Lacosamide

Sales:
€ 1.1 billion (2018)

PatentsExpiration Date
USRE38551March 17, 2022

Dosage : Tablet; Oral
Company : Ucb Inc
Ingredients : Lacosamide
Treatment : Epilepsy and Partial-onset Seizures
ANDA Filing Companies : Alembic,  Amneal,  Aurobindo,  Breckenridge,  Glenmark,  Hetero,  Mylan,  Sandoz,  Sun (Ranbaxy),  Teva,  Watson,  Zydus Cadila

Givlaari
Givosiran

Sales:
$55 Million (2020)

PatentsExpiration Date
US8546143January 9, 2022
US9708610January 1, 2024
US10273477March 8, 2024
US9708615March 8, 2024
US9150605August 28, 2025
US10131907August 24, 2028
US8828956December 4, 2028
US8106022December 12, 2029
US10125364March 15, 2033
US9133461May 14, 2033
US10119143October 3, 2034
US11028392October 3, 2034

Dosage: Subcutaneous injection
Company: Alnylam Pharmaceuticals
Ingredients: GIVOSIRAN SODIUM
Treatment: Acute Hepatic Porphyria

Fusilev
Levoleucovorin

Sales:
$400K (2018)

PatentsExpiration Date
US6500829March 7, 2022

Dosage: Subcutaneous injection
Company: Spectrum Pharma
Ingredients: LEVOLEUCOVORIN CALCIUM
Treatment: Methotrexate

Leqvio
Inclisiran

Sales:

PatentsExpiration Date
US9074213March 9, 2022
US8232383February 20, 2023
US11078485November 4, 2023
US10669544March 8, 2024
US8809292May 10, 2027
US9370582December 4, 2028
US10806791December 4, 2028
US10125369August 18, 2034

Dosage: Subcutaneous injection
Company: Novartis
Ingredients: INCLISIRAN SODIUM
Treatment: Atherosclerotic Cardiovascular Disease and Heterozygous Familial Hypercholesterolemia

Lexiscan
Regadenoson

Sales:
$694 Million (2019)

PatentsExpiration Date
US6403567April 10, 2022
US8106183February 2, 2027

Dosage: Intravenous injection
Company: Astellas Pharma
Ingredients: REGADENOSON
Treatment: Myocardial Perfusion Imaging

Teflaro
Ceftaroline fosamil

Sales:
$153 Million (2019)

PatentsExpiration Date
US6417175April 11, 2022

Dosage: Intravenous injection
Company: Allergan
Ingredients: CEFTAROLINE FOSAMIL
Treatment: Methicillin-resistant Staphylococcus Aureus (MRSA)

Combigan
Brimonidine / Timolol

Sales:
$522 Million (2019)

PatentsExpiration Date
US7642258April 19, 2022

Dosage: Eye Drops
Company: Allergan
Ingredients: BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Treatment: Glaucoma

Cerdelga
Eliglustat

Sales:
€219 million (2020)

PatentsExpiration Date
US6916802April 29, 2022
US7196205June 26, 2026

Dosage: Oral
Company: Genzyme Corporation
Ingredients: ELIGLUSTAT TARTRATE
Treatment: Gaucher’s disease

Lynparza
Olaparib

Sales:
$1.78 Billion (2020)

PatentsExpiration Date
US7151102April 29, 2022
US7449464October 11, 2024
US7981889October 11, 2024
US8247416September 24, 2028

Dosage: Oral
Company: AstraZeneca
Ingredients: OLAPARIB
Treatment: BRCA-mutated Advanced Ovarian Cancer

Epidiolex
Cannabidiol

Sales:
$463.6 million (2021)

PatentsExpiration Date
US10195159May 7, 2022
US11096905October 14, 2035
US11207292April 26, 2039

Dosage: Oral, Inhaled
Company: Greenwich Biosciences
Ingredients: CANNABIDIOL
Treatment: Seizures Associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis

Fycompa
Perampanel

Sales:
$401 million (2018)

PatentsExpiration Date
US6949571June 8, 2022
US8772497July 1, 2026

Dosage: Oral
Company: Eisai Inc.
Ingredients: PERAMPANEL
Treatment: Partial Seizures and Generalized tonic-clonic seizures

Trulance
Plecanatide

Sales:
$82 Million (2020)

PatentsExpiration Date
US7799897June 9, 2022
US7041786January 30, 2028
US10011637June 5, 2034

Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: PLECANATIDE
Treatment: Chronic Idiopathic Constipation and Irritable Bowel Syndrome

Pepaxto
Melphalan flufenamide

Sales:

PatentsExpiration Date
US6992207June 25, 2022

Dosage:
Company: Oncopeptides
Ingredients: MELPHALAN FLUFENAMIDE HYDROCHLORIDE
Treatment: Multiple Myeloma

Caprelsa
Vandetanib

Sales:

PatentsExpiration Date
USRE42353June 27, 2022

Dosage: Oral
Company: Genzyme Corporation
Ingredients: VANDETANIB
Treatment: Medullary thyroid cancer

Stivarga
Regorafenib

Sales:
€411 Million (2019)

PatentsExpiration Date
US7351834June 28, 2022
US8637553February 16, 2031
US9957232July 9, 2032

Dosage: Oral
Company: Bayer
Ingredients: REGORAFENIB
Treatment: Metastatic Colorectal Cancer

Lusedra
Fospropofol

Sales:

PatentsExpiration Date
US6204257July 1, 2022

Dosage: Intravenous
Company: Eisai Inc.
Ingredients: FOSPROPOFOL DISODIUM
Treatment: Used in Diagnostic or Therapeutic procedures such as Endoscopy

Folotyn
Pralatrexate

Sales:
$48 Million (2018)

PatentsExpiration Date
US6028071July 16, 2022

Dosage: Intravenous
Company: Acrotech Biopharma
Ingredients: PRALATREXATE
Treatment: Relapsed or refractory peripheral T-cell lymphoma

Velcade
Bortezomib

Sales:
$930 Million (2020)

PatentsExpiration Date
US6958319July 25, 2022
US6713446July 25, 2022

Dosage: Intravenous
Company: Takeda
Ingredients: BORTEZOMIB
Treatment: Multiple myeloma and mantle cell lymphoma

Slynd
Drospirenone

Sales:
$30 Million (2020)

PatentsExpiration Date
US6441168July 30, 2022

Dosage: Oral
Company: Exeltis USA, Inc.
Ingredients: DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM
Treatment: Birth control pills to prevent pregnancy

Macrilen
Macimorelin

Sales:

PatentsExpiration Date
US6861409August 1, 2022

Dosage: Oral
Company: Æterna Zentaris
Ingredients: MACIMORELIN ACETATE
Treatment: Growth hormone deficiency

Addyi
Flibanserin

Sales:

PatentsExpiration Date
US7420057August 1, 2022

Dosage: Oral
Company: Sprout Pharmaceuticals
Ingredients: FLIBANSERIN
Treatment: Pre-menopausal women with hypoactive sexual desire disorder

Nucynta
Tapentadol

Sales:
$239.5 million (2017)

PatentsExpiration Date
USRE39593August 5, 2022
US7994364June 27, 2025

Dosage: Oral
Company: Collegium Pharmaceutical
Ingredients: TAPENTADOL HYDROCHLORIDE
Treatment: Moderate to severe pain for both acute and chronic musculoskeletal pain

Bylvay
Odevixibat

Sales:
$7 Million (2021)

PatentsExpiration Date
US7132416September 5, 2022
US10975046June 20, 2039

Dosage: Oral
Company: Albireo Pharma
Ingredients: ODEVIXIBAT
Treatment: Progressive familial intrahepatic cholestasis

Abilify
Aripiprazole

Sales:
$332 Million (2020)

PatentsExpiration Date
US8993761September 5, 2022
US9359302September 25, 2022
US8642760March 25, 2023
US8580796March 25, 2023
US8399469June 29, 2025
US10112903June 24, 2030
US8431576October 26, 2030

Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: ARIPIPRAZOLE
Treatment: Schizophrenia and bipolar disorder

Myrbetriq
Mirabegron

Sales:
$1.5 Billion (2018)

PatentsExpiration Date
US6346532September 27, 2022
US7342117May 4, 2024

Dosage: Oral
Company: Astellas Pharma
Ingredients: MIRABEGRON
Treatment: Overactive bladder

Lupkynis
Voclosporin

Sales:
$45.5 Million (2021)

PatentsExpiration Date
US7332472October 17, 2022

Dosage: Oral
Company: Aurinia Pharmaceuticals
Ingredients: VOCLOSPORIN
Treatment: Attack of lupus nephritis

Movantik
Naloxegol

Sales:
$96 Million (2019)

PatentsExpiration Date
US7662365October 18, 2022
US7786133September 16, 2028
US9012469April 2, 2032

Dosage: Oral
Company: AstraZeneca
Ingredients: NALOXEGOL OXALATE
Treatment: Opioid-induced constipation

Neurontin
Gabapentin

Sales:

PatentsExpiration Date
US8048917November 6, 2022
US6818787April 6, 2025
US8026279November 10, 2026

Dosage: Oral
Company: Pfizer
Ingredients: GABAPENTIN ENACARBIL
Treatment: Partial seizures and neuropathic pain

Chantix
Varenicline

Sales:
$1.1 Billion (2019)

PatentsExpiration Date
US6890927November 6, 2022
US7265119February 3, 2023

Dosage: Nasal spray
Company: Pfizer
Ingredients: VARENICLINE TARTRATE
Treatment: Smoking cessation

Ocaliva
Obeticholic acid

Sales:
$363.5 million (2021)

PatentsExpiration Date
US7138390November 16, 2022
USRE48286February 21, 2027
US10174073June 17, 2033

Dosage: Oral
Company: Intercept Pharmaceuticals
Ingredients: OBETICHOLIC ACID
Treatment: Primary biliary cholangitis

Norvasc
Amlodipine

Sales:
$363.5 million (2021)

PatentsExpiration Date
US6828339November 20, 2022
US6696481April 15, 2023
US7846961October 5, 2029

Dosage: Oral
Company: VIATRIS
Ingredients: AMLODIPINE BESYLATE
Treatment: High blood pressure and coronary artery disease

Viibryd
Vilazodone

Sales:

PatentsExpiration Date
US7834020December 5, 2022
US8673921December 5, 2022

Dosage: Oral
Company: Allergan
Ingredients: VILAZODONE HYDROCHLORIDE
Treatment: Major depressive disorder

Taflotan
Tafluprost

Sales:
$180 Million (2020) Est.

PatentsExpiration Date
US5886035December 18, 2022

Dosage: Eye Drops
Company: Santen Pharmaceutical
Ingredients: TAFLUPROST
Treatment: Open-angle Glaucoma

Hetlioz
Tasimelteon

Sales:
$173.5 Million (2021)

PatentsExpiration Date
US5856529December 9, 2022
US10829465February 12, 2035
US10071977February 12, 2035

Dosage: Oral
Company: Vanda Pharmaceuticals
Ingredients: TASIMELTEON
Treatment: Non-24-hour sleep-wake disorder

Showing 3 comments
  • Dr. Raghu Ram
    Reply

    An Excellent work was done, this data is really useful.

  • Yuvaraju
    Reply

    Descriptive data collection and presented well, Goog Job.

  • Dr Amita Karnik
    Reply

    This data is an excellent collection, got the immediate requirement for strategic decisions.

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.